Molecular Pathogenesis of Myeloproliferative Neoplasms

[61] Cristobal I(2021)Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study Blood Adv 10 99-21

[62] Fourouclas N(2018)SRSF2 mutations drive oncogenesis by activating a global program of aberrant alternative splicing in hematopoietic cells Leukemia 1 21-102

[63] Li J(2018)Srsf2P95H initiates myeloid bias and myelodysplastic/myeloproliferative syndrome from hemopoietic stem cells Blood 119 4480-1199

[64] Gilby DC(2020)ASXL1 mutation confers poor prognosis in primary myelofibrosis patients with low JAK2V617F allele burden but not in those with high allele burden Blood Cancer J 119 558-397

[65] Campbell PJ(2016)Targeted deep sequencing in polycythemia vera and essential thrombocythemia Blood Adv 80 197-318

[66] Beer PA(2012)Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome Blood 108 3626-499

[67] Boyd EM(2002)Exploring polycythaemia vera with fluorescence in situ hybridization: additional cryptic 9p is the most frequent abnormality detected Br J Haematol 83 17-3589

[68] Nangalia J(2008)Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates Eur J Haematol 98 96-undefined

[69] Massie CE(2006)Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance Blood 116 318-undefined

[70] Baxter EJ(2009)Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance Eur J Haematol 104 2425-undefined

[61] Cristobal I(2021)Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study Blood Adv 10 99-21

[62] Fourouclas N(2018)SRSF2 mutations drive oncogenesis by activating a global program of aberrant alternative splicing in hematopoietic cells Leukemia 1 21-102

[63] Li J(2018)Srsf2P95H initiates myeloid bias and myelodysplastic/myeloproliferative syndrome from hemopoietic stem cells Blood 119 4480-1199

[64] Gilby DC(2020)ASXL1 mutation confers poor prognosis in primary myelofibrosis patients with low JAK2V617F allele burden but not in those with high allele burden Blood Cancer J 119 558-397

[65] Campbell PJ(2016)Targeted deep sequencing in polycythemia vera and essential thrombocythemia Blood Adv 80 197-318

[66] Beer PA(2012)Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome Blood 108 3626-499

[67] Boyd EM(2002)Exploring polycythaemia vera with fluorescence in situ hybridization: additional cryptic 9p is the most frequent abnormality detected Br J Haematol 83 17-3589

[68] Nangalia J(2008)Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates Eur J Haematol 98 96-undefined

[69] Massie CE(2006)Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance Blood 116 318-undefined

[70] Baxter EJ(2009)Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance Eur J Haematol 104 2425-undefined